Expert opinion on meningococcal B vaccine – information and suggestions to EU/EEA countries
The ECDC expert opinion provides information on the burden of serogroup B invasive meningococcal disease in the EU/EEA, includes general considerations for 4CMenB introduction such as vaccine immunogenicity, safety, cost-effectiveness, ease of implementation and areas for country collaboration, and highlights different options for vaccine introduction.
EIW 2015 at ECDC
On the occasion of the tenth anniversary of European Immunization Week, ECDC is releasing a new complement of data, tools, blogs and updates to support public health authorities in their work against vaccine preventable diseases.
Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, ItalyArchived
Findings in this study confirmed the herd immunity effect of immunizing young children, since invasive meningococcal disease was not only reduced among vaccinees, but in all age groups.
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules – A randomized controlled trialArchived
4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.